Immune checkpoint inhibitors such as anti-PD-1/PD-L1 and anti-CTLA-4 antagonists, which function by activating the adaptive immune system against tumor cells, have revolutionized cancer therapy. This evidence concerns the gene CTLA4 and neoplasm.